RxSight amends bylaws to update director nomination procedures and conform to Delaware law

RxSight, Inc.

Amended bylaws require stockholders nominating directors to provide evidence of compliance with Rule 14a-19 at least five business days before meeting.
Revised stockholder meeting procedures and board action by written consent to conform to recent DGCL amendments.
Updated provisions regarding directors, Board committees, and officers; made ministerial and conforming changes.
Bylaw amendments effective December 9, 2022, approved by Board on recommendation of Corporate Governance and Nominating Committee.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

RxSight, Inc.: Amended and restated bylaws to revise director nomination procedures, stockholder meeting procedures, and conform to DGCL amendments (effective 2022-12-09).

Change: bylaw amendment
Effective: 2022-12-09

Exact text from the filing

On December 9, 2022, the Board of Directors (the “Board”) of RxSight, Inc. (the “Company”), acting upon the recommendation of the Corporate Governance and Nominating Committee of the Board, amended and restated the Company’s amended and restated bylaws, effective immediately.

View on SEC.gov

Browse all governance changes →

RxSight, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-026362

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.